Increased effects of MPDAX, a novel xanthine derivative, on antitumor activity of doxorubicin

Toxicology Letters

Volumn 150, Issue 3, 2004, Pages 341-349

  Sadzuka, Yasuyuki ^a   Sugiyama, Tomomi ^a   Suzuki, Hirokazu ^b   Sawanishi, Hiroyuki ^b   Miyamoto, Ken Ichi ^c  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

1 methyl 3 propyl 7 N,N dimethylpropylamide xanthine; DOX; Doxorubicin; MPDAX; Permeability; Resistance; Xanthine derivative

Indexed keywords

1 METHYL 3 PROPYL 7 N,N DIMETHYLPROPYLAMIDE XANTHINE; ANTINEOPLASTIC AGENT; DOXORUBICIN; NUCLEOSIDE TRANSPORTER; THYMIDINE; UNCLASSIFIED DRUG; URIDINE; XANTHINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MEMBRANE TRANSPORT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG POTENTIATION; DRUG TRANSPORT; DRUG TUMOR LEVEL; EHRLICH ASCITES TUMOR; LEUKEMIA P 388; MALE; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; DOXORUBICIN; DRUG SYNERGISM; MALE; MICE; MICE, INBRED STRAINS; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; THYMIDINE; TISSUE DISTRIBUTION; URIDINE; XANTHINES;

EID: 1942421244     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2004.02.005     Document Type: Article

References (25)

1. Borst P., Evers R., Kool M., Wijnholds J. The multidrug resistance protein family. Biochim. Biophys. Acta. 1461:1999;347-357.
2. Crawford C.R., Ng C.Y.H., Noel D., Belt J. Nucleoside transport in L1210 murine leukemia cells. J. Biol. Chem. 265:1990;9732-9736.
3. Griffith D.A., Jarvis S.M. Nucleoside and nucleobase transport systems of mammalian cells. Biochim. Biophys. Acta. 1286:1996;153-181.
4. Kakuyama A., Sadzuka Y. Effect of methylxanthine derivatives on doxorubicin Transport and antitumor activity. Curr. Drug Met. 2:2001;379-395.
5. Kool M., Haas M., Scheffer G.L., Scheper R.J., Van Eijk M.J.T., Juijin J.A., Baas F., Borst P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene(MRP1), in human cancer cell lines. Cancer Res. 57:1997;3537-3547.
6. Kool M., Linden M., Haas M., Baas F., Borst P. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissue and cancer cells. Cancer Res. 59:1999;175-182.
7. Nagasawa K., Ohnishi N., Yokoyama T. Transport mechanisms of idarubicin, an anthracycline derivative, in human leukemia HL60 cells and mononuclear cells, and comparison with those of its analogs. Jpn. J. Cancer Res. 88:1997;750-759.
8. Nagasawa K., Ohnishi N., Yokoyama T. Possibility of contribution of nucleoside transport systems to pirarubicin uptake by HL60 cells but not mononuclear cells. Jpn. J. Cancer Res. 89:1998;673-680.
9. Nagasawa K., Fumihara T., Ohnishi N., Yokoyama T. Contribution of the nucleoside transport system to doxorubicin transport in HL60 cells but not in mononuclear cells. Jpn. J. Cancer Res. 90:1999;781-787.
10. Plagemann P.G.W., Wohlhueter R.M. Nucleoside transport in cultured mammalian cells, multiple forms with different sensitivity to inhibition by nitrobenzylthioinosine or hypoxanthine. Biochim. Biophys. Acta. 773:1984a;39-52.
11. Plagemann P.G.W., Wohlhueter R.M. Inhibition of the transport of adenosine, other nucleosides and hypoxanthine in Novikoff rat hepatoma cells by methylxanthines, papaverine, N6-cyclohexyladenosine and N6- phenylisopropyladenosine. Biochem. Pharmacol. 33:1984b;1783-1788.
12. Plagemann P.G.W., Wohlhueter R.M., Woffendin C. Nucleoside and nucleobase transport in animal cells. Biochim. Biophys. Acta. 947:1988;405-443.
13. Sadzuka Y., Mochizuki E., Takino Y. Caffeine modulates the antitumor activity and toxic side effects of adriamycin. Jpn. J. Cancer Res. 84:1993;348-353.
14. Sadzuka Y., Mochizuki E., Iwazaki A., Hirota S., Takino Y. Caffeine enhances adriamycin antitumor activity in Ehrlich ascites carcinoma-bearing mice. Biol. Pharm. Bull. 18:1995a;159-161.
15. Sadzuka Y., Mochizuki E., Takino Y. Mechanism of caffeine modulation of the antitumor activity of adriamycin. Toxicol. Lett. 75:1995b;39-49.
16. Sadzuka Y., Iwazaki E., Miyagishima A., Nozawa Y., Hirota S. Effects of methylxanthine derivatives on adriamycin concentration and antitumor activity. Jpn. J. Cancer Res. 86:1995c;594-599.
17. Sadzuka Y., Iwazaki A., Sugiyama T., Sawanishi H., Miyamoto K. 1-Methyl-3-propyl-7-butylxanthine, a novel biochemical modulator, enhances therapeutic efficacy of adriamycin. Jpn. J. Cancer Res. 89:1998;228-233.
18. Sadzuka Y., Sugiyama T., Sawanishi H., Miyamoto K. Enhanced efficacy of 1-methyl-3-propyl-7-butylxanthine on the antitumor activity of doxorubicin against doxorubicin-resistant P388 leukemia. Cancer Lett. 138:1999;5-11.
19. Sadzuka Y., Egawa Y., Sawanishi H., Miyamoto K., Sonobe T. Effects of xanthine derivatives on the influx and efflux of doxorubicin in P388 and DOX-resistant P388 leukemia cells. Toxicol. Lett. 135:2002;137-144.
20. Siegfried J.M., Burke T.G., Tritton T.R. Cellular transport of anthracycline by passive diffusion. Biochem. Pharmacol. 34:1985;593-598.
21. Skovsgaard T. Transport and binding of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells. Biochem. Pharmacol. 26:1977a;215-222.
22. Skovsgaard T. Mechanisms of resistance to daunorubicin in Ehrlich ascites tumour cells. Cancer Res. 38:1978a;1785-1791.
23. Skovsgaard T. Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumour cells. Cancer Res. 38:1978b;4722-4727.
24. Skovsgaard T. Carrier-mediated transport of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells. Biochem. Pharmacol. 26:1977b;1221-1227.
25. Zou Y., Ling Y.H., Van N.T., Priebe W., Perez-Soler R. Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline with non-cross resistance properties. Cancer Res. 54:1994;1479-1484.